|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Graboyes EM, Townsend ME, Kallogjeri D,
Piccirillo JF and Nussenbaum B: Evaluation of quality metrics for
surgically treated laryngeal squamous cell carcinoma. JAMA
Otolaryngol Head Neck Surg. 142:1154–1163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marioni G, Marchese-Ragona R, Cartei G,
Marchese F and Staffieri A: Current opinion in diagnosis and
treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mantsopoulos K, Psychogios G, Bohr C, Zenk
J, Kapsreiter M, Waldfahrer F and Iro H: Primary surgical treatment
of T3 glottic carcinoma: Long-term results and decision-making
aspects. Laryngoscope. 122:2723–2727. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim JC and Donaldson PJ: Focus on
molecules: The cystine/glutamate exchanger (System xc).
Exp Eye Res. 92:162–163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lewerenz J, Hewett SJ, Huang Y, Lambros M,
Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M,
et al: The cystine/glutamate antiporter system xc in
health and disease: From molecular mechanisms to novel therapeutic
opportunities. Antioxid Redox Signal. 18:522–555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Estrela JM, Ortega A and Obrador E:
Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci.
43:143–181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koizume S and Miyagi Y: Lipid droplets: A
key cellular organelle associated with cancer cell survival under
normoxia and hypoxia. Int J Mol Sci. 17:1430–1453. 2016. View Article : Google Scholar :
|
|
9
|
Bhutia YD, Babu E, Ramachandran S and
Ganapathy V: Amino Acid transporters in cancer and their relevance
to ‘glutamine addiction’: Novel targets for the design of a new
class of anticancer drugs. Cancer Res. 75:1782–1788. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiozaki A, Iitaka D, Ichikawa D,
Nakashima S, Fujiwara H, Okamoto K, Kubota T, Komatsu S, Kosuga T,
Takeshita H, et al: xCT, component of cysteine/glutamate
transporter, as an independent prognostic factor in human
esophageal squamous cell carcinoma. J Gastroenterol. 49:853–863.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert SM, Buckingham SC, Campbell SL,
Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid
MA, Eschbacher JM, et al: SLC7A11 expression is associated with
seizures and predicts poor survival in patients with malignant
glioma. Sci Transl Med. 7:289ra862015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okuno S, Sato H, Kuriyama-Matsumura K,
Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T and Bannai
S: Role of cystine transport in intracellular glutathione level and
cisplatin resistance in human ovarian cancer cell lines. Br J
Cancer. 88:951–956. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewerenz J, Maher P and Methner A:
Regulation of xCT expression and system xc function in
neuronal cells. Amino Acids. 42:171–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lo M, Ling V, Low C, Wang YZ and Gout PW:
Potential use of the anti-inflammatory drug, sulfasalazine, for
targeted therapy of pancreatic cancer. Curr Oncol. 17:9–16.
2010.PubMed/NCBI
|
|
15
|
Timmerman LA, Holton T, Yuneva M, Louie
RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, et
al: Glutamine sensitivity analysis identifies the xCT antiporter as
a common triple-negative breast tumor therapeutic target. Cancer
Cell. 24:450–465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, Song
M, Yang J, Wen S, Xu RH, Hu Y, et al: Xc inhibitor sulfasalazine
sensitizes colorectal cancer to cisplatin by a GSH-dependent
mechanism. Cancer Lett. 368:88–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang R, Guo Y, Ma H, Feng L, Wang Q, Chen
X, Lian M, Wang H and Fang J: Tumor necrosis factor superfamily
member 13 is a novel biomarker for diagnosis and prognosis and
promotes cancer cell proliferation in laryngeal squamous cell
carcinoma. Tumour Biol. 37:2635–2645. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stefanowicz-Hajduk J, Sparzak-Stefanowska
B, Krauze-Baranowska M and Ochocka JR: Securinine from Phyllanthus
glaucus induces cell cycle arrest and apoptosis in human cervical
cancer HeLa cells. PLoS One. 11:e01653722016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anderson CL, Iyer SS, Ziegler TR and Jones
DP: Control of extracellular cysteine/cystine redox state by HT-29
cells is independent of cellular glutathione. Am J Physiol Regul
Integr Comp Physiol. 293:R1069–R1075. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lo M, Wang YZ and Gout PW: The
xc cystine/glutamate antiporter: A potential target for
therapy of cancer and other diseases. J Cell Physiol. 215:593–602.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gout PW, Buckley AR, Simms CR and
Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth
by inhibition of the xc cystine transporter: A new
action for an old drug. Leukemia. 15:1633–1640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge
C, Liang L, Jia D, Chen T, Yao M, et al: Disruption of xCT inhibits
cell growth via the ROS/autophagy pathway in hepatocellular
carcinoma. Cancer Lett. 312:55–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pezzilli R, Partelli S, Cannizzaro R,
Pagano N, Crippa S, Pagnanelli M and Falconi M: Ki-67 prognostic
and therapeutic decision driven marker for pancreatic
neuroendocrine neoplasms (PNENs): A systematic review. Adv Med Sci.
61:147–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheah PL and Looi LM: p53: an overview of
over two decades of study. Malays J Pathol. 23:9–16.
2001.PubMed/NCBI
|
|
25
|
Wang SJ and Gu W: To be, or not to be:
Functional dilemma of p53 metabolic regulation. Curr Opin Oncol.
26:78–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bieging KT and Attardi LD: Deconstructing
p53 transcriptional networks in tumor suppression. Trends Cell
Biol. 22:97–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brady CA, Jiang D, Mello SS, Johnson TM,
Jarvis LA, Kozak MM, Broz D Kenzelmann, Basak S, Park EJ,
McLaughlin ME, et al: Distinct p53 transcriptional programs dictate
acute DNA-damage responses and tumor suppression. Cell.
145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang L, Kon N, Li T, Wang SJ, Su T,
Hibshoosh H, Baer R and Gu W: Ferroptosis as a p53-mediated
activity during tumour suppression. Nature. 520:57–62. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao JY and Dixon SJ: Mechanisms of
ferroptosis. Cell Mol Life Sci. 73:2195–2209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dixon SJ, Patel DN, Welsch M, Skouta R,
Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS,
et al: Pharmacological inhibition of cystine-glutamate exchange
induces endoplasmic reticulum stress and ferroptosis. Elife.
3:e025232014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu H, Guo P, Xie X, Wang Y and Chen G:
Ferroptosis, a new form of cell death, and its relationships with
tumourous diseases. J Cell Mol Med. 21:648–657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Golubnitschaja O: Cell cycle checkpoints:
The role and evaluation for early diagnosis of senescence,
cardiovascular, cancer, and neurodegenerative diseases. Amino
Acids. 32:359–371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Visconti R, Monica R Della and Grieco D:
Cell cycle checkpoint in cancer: a therapeutically targetable
double-edged sword. J Exp Clin Cancer Res. 35:1532016. View Article : Google Scholar : PubMed/NCBI
|
